arrow
U

Uma Borate

University System of Ohio
H指数:33
被引数:7,716

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms

国际骨髓增生异常综合征/骨髓肿瘤工作组关于骨髓报告标准化的共识

2025-10-010
OA
Real-world experience of venetoclax target dosing with concomitant posaconazole in adult patients with acute myeloid leukemia

成人急性髓系白血病患者接受维奈克拉 target dosing 并联泊沙康唑的实况经验

2025-09-230
OAAI
Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS

他米巴罗替与阿扎胞苷联合治疗新诊断高危骨髓增生异常综合征(MDS)的SELECT-MDS-1三期研究的关键结果

2025-05-090
OAAI
Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial

新诊断急性髓系白血病60岁及以上患者的分子特征分析:Beat AML临床试验报告

2025-04-030
OA
Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/SyndromesdRecommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS])

骨髓增生异常肿瘤/综合征的诊断和分类的当代方法国际骨髓增生异常肿瘤/综合征联合会 (MDS [icMDS]) 的建议

2024-12-011
PRE
IDH2 Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy

IDH2突变与接受低强度治疗的新诊断急性髓系白血病老年患者的良好预后相关。

BLOOD
IF23.1
2024-11-051
PRE
Real-World Experience of Venetoclax Target Dosing with Concomitant Posaconazole in Adult Patients with Acute Myeloid Leukemia

急性髓系白血病成人患者中,与泊沙康唑联合使用的维奈克拉靶向剂量给药的实战经验

BLOOD
IF23.1
2024-11-050
PRE
Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age

新诊断、老年急性髓系白血病患者在Venetoclax/阿扎胞苷时代的Beat AML主试验中的结局与生存情况

BLOOD
IF23.1
2024-11-050
PRE
Phase 1 Trial Testing the Novel Combination Therapy of Entrectinib and ASTX727 in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia Patients

I期临床试验:评估Entrectinib与ASTX727新型联合疗法在TP53突变复发/难治性急性髓系白血病患者中的疗效

BLOOD
IF23.1
2024-11-050
PRE
A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination with Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia

一项I期研究,旨在评估吉姆单抗奥佐米星和米哚妥林在联合标准剂量阿糖胞苷和柔红霉素诱导治疗新诊断FLT3突变急性髓性白血病时的安全性与耐受性。

BLOOD
IF23.1
2024-11-050
PRE
Comparison of Two Myeloablative Total-Body Irradiation (MAC-TBI) Regimens: 1200 Cgy Vs 800 Cgy of TBI for Allogeneic Stem Cell Transplantation in Adults with Hematological Malignancies

比较两种骨髓清除性全身照射(MAC-TBI)方案:用于成人血液系统恶性肿瘤异基因干细胞移植的1200 Cgy与800 Cgy TBI剂量比较

BLOOD
IF23.1
2024-11-050
PRE
GATA2-Mutated AML: Clinical Outcomes and Spectrum of Infections in Patients Undergoing or Not Allogeneic Stem Cell Transplantation

GATA2突变AML:接受或不接受异基因干细胞移植患者的临床结局及感染谱

BLOOD
IF23.1
2024-11-050
PRE
A Multicenter, Open-Label, Phase 1 Clinical Trial of AJ1-11095 Administered As Oral Monotherapy in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed By a Type I JAK2 Inhibitor (JAK2i)

一项多中心、开放标签、I期临床试验,评估AJ1-11095以口服单药疗法给药在曾接受过I型JAK2抑制剂(JAK2i)治疗失败的原发性骨髓纤维化(PMF)、真性红细胞增多症后骨髓纤维化(PPV-MF)或原发性血小板增多症后骨髓纤维化(PET-MF)患者中的疗效。

BLOOD
IF23.1
2024-11-050
PRE
A Randomized Phase 2 Trial of 28-Day (Arm A) Versus 14-Day (Arm B) Schedule of Venetoclax plus Azacitidine in Newly Diagnosed Acute Myeloid Leukemia Patients ≥ 60 Years

一项随机Ⅱ期临床试验,比较28天(A组)与14天(B组)方案下Venetoclax联合Azacitidine治疗初诊急性髓系白血病患者(≥60岁)的效果。

BLOOD
IF23.1
2024-11-050
PRE
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy

Beat-aml 2024 ELN-对新诊断AML的老年人进行低强度治疗的风险分层

2024-10-102
OAAI